Denosumab for prevention of fractures in postmenopausal women with osteoporosis SR Cummings, JS Martin, MR McClung, ES Siris, R Eastell, IR Reid, ... New England Journal of Medicine 361 (8), 756-765, 2009 | 3996 | 2009 |
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 … JP Brown, RL Prince, C Deal, RR Recker, DP Kiel, LH De Gregorio, ... Journal of bone and mineral research 24 (1), 153-161, 2009 | 790 | 2009 |
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized … PD Miller, MA Bolognese, EM Lewiecki, MR McClung, B Ding, M Austin, ... Bone 43 (2), 222-229, 2008 | 666 | 2008 |
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension S Papapoulos, R Chapurlat, C Libanati, ML Brandi, JP Brown, ... Journal of Bone and Mineral Research 27 (3), 694-701, 2012 | 455 | 2012 |
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures M Austin, YC Yang, E Vittinghoff, S Adami, S Boonen, DC Bauer, ... Journal of Bone and Mineral Research 27 (3), 687-693, 2012 | 182 | 2012 |
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial JP Brown, C Roux, O Törring, PR Ho, JE Beck Jensen, N Gilchrist, ... Journal of Bone and Mineral Research 28 (4), 746-752, 2013 | 175 | 2013 |
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX EV McCloskey, H Johansson, A Oden, M Austin, E Siris, A Wang, ... Journal of Bone and Mineral Research 27 (7), 1480-1486, 2012 | 161 | 2012 |
Differing effects of denosumab and alendronate on cortical and trabecular bone RM Zebaze, C Libanati, M Austin, A Ghasem-Zadeh, DA Hanley, ... Bone 59, 173-179, 2014 | 157 | 2014 |
Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials M Hedenus, J Vansteenkiste, D Kotasek, M Austin, RG Amado Journal of clinical oncology 23 (28), 6941-6948, 2005 | 96 | 2005 |
Amg Bone Loss Study Group: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting … PD Miller, MA Bolognese, EM Lewiecki, MR McClung, B Ding, M Austin, ... Bone 43 (2), 222-229, 2008 | 56 | 2008 |
The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel EA Bower, JL Moore, M Moss, KA Selby, M Austin, S Meeves Aviation, space, and environmental medicine 74 (2), 145-152, 2003 | 48 | 2003 |
Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis C Bugos Diabetes Res Clin Pract 50, S47, 2000 | 44 | 2000 |
The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy E Seeman, C Libanati, M Austin, R Chapurlat, SK Boyd, R Zebaze, ... J Bone Miner Res 26 (Suppl 1), S22, 2011 | 23 | 2011 |
Centralized statistical monitoring of clinical trial enrollment performance V Anisimov, M Austin Communications in Statistics: Case Studies, Data Analysis and Applications 6 …, 2020 | 10 | 2020 |
Effect of densoumab vs alendronate on bone turnover markers and bone mineral density changes at 12 months based on baseline bone turnover level JP Brown, C Deal, LH de Gregorio, LC Hofbauer, H Wang, M Austin, ... JOURNAL OF BONE AND MINERAL RESEARCH 23, S80-S80, 2008 | 7 | 2008 |
DENOSUMAB REDUCES THE RISK OF CLINICAL OSTEOPOROTIC FRACTURES IN POSTMENOPAUSAL WOMEN, PARTICULARLY IN THOSE WITH MODERATE TO HIGH FRACTURE RISK AS ASSESSED WITH FRAX (R) E McCloskey, M Lewiecki, J Kanis, H Johansson, A Oden, M Austin, ... OSTEOPOROSIS INTERNATIONAL 22, 103-103, 2011 | 5 | 2011 |
Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy RE Smith Jr, JA Glaspy, NS Tchekmedyian, MD Austin, JD Kallich Supportive cancer therapy 1 (1), 49-54, 2003 | 5 | 2003 |
Effects of single dose fexofenadine, diphenhydramine, and placebo on cognitive and psychomotor performance in naval flight personnel in a double‐blind, crossover randomised study E Bower, J Moore, M Moss, K Selby, M Austin, S Meeves Allergy 55 (Suppl 63), 912, 2000 | 5 | 2000 |
Forecasting and optimizing patient enrolment in clinical trials under various restrictions V Anisimov, M Austin International Conference on Stochastic Processes and Algebraic Structures …, 2019 | 4 | 2019 |
Graphical analyses of clinical trial safety data H Ma, K Zhou, A Xia, M Austin, G Li, M O’Connell Joint statistical meeting-statistical computing and statistical graphics …, 2007 | 4 | 2007 |